730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors

• Yuman Fong,
• Amanda Seiz,
• Hirva Mamdani,
• Melissa Polasek,
• Daneng Li,
• Leslie Chong,
• Alexander I Spira,
• Jennifer Leddon,
• Seymour Fein,
• Nick Ede,
• Ursula McCurry,
• Sharon Yavrom,
• Giovanni Selvaggi

Affiliations

Yuman Fong

1City of Hope, Duarte, CA, USA

Amanda Seiz

5Imugene Ltd, Sydney, NSW, Australia

Hirva Mamdani

1Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

Melissa Polasek

6Chapel Hill, NC, USA

Daneng Li

1City of Hope, Duarte, CA, USA

Leslie Chong

5Imugene Ltd, Sydney, NSW, Australia

Alexander I Spira

2Next Oncology, Fairfax, VA, USA

Jennifer Leddon

4University of Cincinnati, Cincinnati, OH, USA

Seymour Fein

5Imugene Ltd, Sydney, NSW, Australia

Nick Ede

5Imugene Ltd, Sydney, NSW, Australia

Ursula McCurry

5Imugene Ltd, Sydney, NSW, Australia

Sharon Yavrom

5Imugene Ltd, Sydney, NSW, Australia

Giovanni Selvaggi

ENB Therapeutics, New York, NY, USA